Neuroimaging in mitochondrial disease.

Distelmaier, Felix; Klopstock, Thomas

doi:10.1016/b978-0-12-821751-1.00016-6

Journal Article (Review Article)

DZNE-2023-00294

Neuroimaging in mitochondrial disease.

Distelmaier, F. ; Klopstock, T. (Last author)DZNE*

2023
Elsevier Amsterdam [u.a.]

Handbook of clinical neurology 194, 173-185 (2023) [10.1016/b978-0-12-821751-1.00016-6]

This record in other databases:

Please use a persistent id in citations: doi:10.1016/B978-0-12-821751-1.00016-6 doi:10.1016/b978-0-12-821751-1.00016-6

Abstract: The anatomic complexity of the brain in combination with its high energy demands makes this organ specifically vulnerable to defects of mitochondrial oxidative phosphorylation. Therefore, neurodegeneration is a hallmark of mitochondrial diseases. The nervous system of affected individuals typically shows selective regional vulnerability leading to distinct patterns of tissue damage. A classic example is Leigh syndrome, which causes symmetric alterations of basal ganglia and brain stem. Leigh syndrome can be caused by different genetic defects (>75 known disease genes) with variable disease onset ranging from infancy to adulthood. Other mitochondrial diseases are characterized by focal brain lesions, which is a core feature of MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes). Apart from gray matter, also white matter can be affected by mitochondrial dysfunction. White matter lesions vary depending on the underlying genetic defect and may progress into cystic cavities. In view of the recognizable patterns of brain damage in mitochondrial diseases, neuroimaging techniques play a key role in diagnostic work-up. In the clinical setting, magnetic resonance imaging (MRI) and MR spectroscopy (MRS) are the mainstay of diagnostic work-up. Apart from visualization of brain anatomy, MRS allows the detection of metabolites such as lactate, which is of specific interest in the context of mitochondrial dysfunction. However, it is important to note that findings like symmetric basal ganglia lesions on MRI or a lactate peak on MRS are not specific, and that there is a broad range of disorders that can mimic mitochondrial diseases on neuroimaging. In this chapter, we will review the spectrum of neuroimaging findings in mitochondrial diseases and discuss important differential diagnoses. Moreover, we will give an outlook on novel biomedical imaging tools that may provide interesting insights into mitochondrial disease pathophysiology.

Keyword(s): Humans (MeSH) ; Leigh Disease: diagnosis (MeSH) ; Leigh Disease: pathology (MeSH) ; Magnetic Resonance Imaging: methods (MeSH) ; Neuroimaging: methods (MeSH) ; Brain: pathology (MeSH) ; Mitochondrial Diseases: genetics (MeSH) ; MELAS Syndrome: diagnosis (MeSH) ; MELAS Syndrome: pathology (MeSH) ; Lactic Acid (MeSH) ; Brain ; Central nervous system ; Leigh disease ; Magnetic resonance imaging ; Neurodegeneration ; OXPHOS ; Lactic Acid